Meeting
2023 ASCO Annual Meeting
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.
Authors
Evelyn Cantillo
525 East 68th St, New York, NY
Evelyn Cantillo , Tyler J. Zemla , John William Moroney , Edwin A Alvarez , Lauren Yauch , Yvonne Gail Lin , JaneMichelle Michelle Brockman , Gillian DiLallo , Joyce F. Liu , Angeles Alvarez Secord , Andrew B. Nixon , Sumithra J. Mandrekar , Ursula A. Matulonis , David E. Kozono , Brian M. Slomovitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT04486352
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5634)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5634
Abstract #
TPS5634
Poster Bd #
318a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2023 ASCO Annual Meeting
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.
First Author: Drew W. Rasco
Poster
2021 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2020 ASCO Virtual Scientific Program
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
First Author: Christian Marth